Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

E-6060, a potential new therapy for antibody-dependent autoimmune diseases

Oct. 30, 2000

Inflammatory and autoimmune disease treatment enters phase I testing

Oct. 26, 2000

FDA grants priority review status to Genelabs' NDA for new lupus therapy

Oct. 26, 2000

Remicade recommended for approval in Europe for broader application

Oct. 26, 2000

MitoKor and UCSD receive BioSTAR grant for osteoarthritis research

Oct. 26, 2000

Phase III trial of lupus drug LJP-394 begins

Oct. 25, 2000

Celebrex introduced in major European market

Oct. 23, 2000

NO-releasing paracetamol derivative exerts both analgesic and antiinflammatory effects

Oct. 20, 2000

Dimethaid Research seeks approval for topical osteoarthritis treatment in Canada

Oct. 18, 2000

Novel antiinflammatory/immunomodulatory agents identified at Kowa

Oct. 17, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...